{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:13:59Z","timestamp":1787616839908,"version":"build-2736575974"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Key R and D Program of China","award":["2022YFC3600504"],"award-info":[{"award-number":["2022YFC3600504"]}]},{"name":"the Science and Technology Innovation 2030-Major Project","award":["2021ZD0201806"],"award-info":[{"award-number":["2021ZD0201806"]}]},{"DOI":"10.13039\/501100005090","name":"the Beijing Nova Program","doi-asserted-by":"crossref","award":["20240484612"],"award-info":[{"award-number":["20240484612"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40263-025-01228-x","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:47:32Z","timestamp":1759218452000},"page":"215-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety Outcomes Following Intravenous Thrombolysis in Acute Ischemic Stroke: A Systematic Review and Network Meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Xuefan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aini","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houlin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-3894","authenticated-orcid":false,"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"10","key":"1228_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","volume":"20","author":"GBDS Collaborators","year":"2021","unstructured":"Collaborators GBDS. Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795\u2013820.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1228_CR2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/archneurol.2010.175","volume":"67","author":"JN Goldstein","year":"2010","unstructured":"Goldstein JN, Marrero M, Masrur S, Pervez M, Barrocas AM, Abdullah A, et al. Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Arch Neurol. 2010;67(8):965\u20139.","journal-title":"Arch Neurol"},{"issue":"9","key":"1228_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1001\/jamaneurol.2014.1210","volume":"71","author":"S Yaghi","year":"2014","unstructured":"Yaghi S, Eisenberger A, Willey JZ. Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment. JAMA Neurol. 2014;71(9):1181\u20135.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1228_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1212\/WNL.0b013e3182267b8c","volume":"77","author":"D Strbian","year":"2011","unstructured":"Strbian D, Sairanen T, Meretoja A, Pitkaniemi J, Putaala J, Salonen O, et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011;77(4):341\u20138.","journal-title":"Neurology"},{"issue":"24","key":"1228_CR5","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"National Institute of Neurological, Stroke rt PASSG","year":"1995","unstructured":"National Institute of Neurological, Stroke rt PASSG. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581\u20137.","journal-title":"N Engl J Med"},{"issue":"10377","key":"1228_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","volume":"401","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023;401(10377):645\u201354.","journal-title":"Lancet"},{"issue":"8","key":"1228_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMoa2310392","volume":"390","author":"GW Albers","year":"2024","unstructured":"Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection. N Engl J Med. 2024;390(8):701\u201311.","journal-title":"N Engl J Med"},{"key":"1228_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.924747","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Cui R, Fan F, Lu Y, Ai Y, Liu H, et al. The efficacy and safety of ischemic stroke therapies: an umbrella review. Front Pharmacol. 2022;13:924747.","journal-title":"Front Pharmacol"},{"key":"1228_CR9","doi-asserted-by":"publisher","first-page":"175628642312213","DOI":"10.1177\/17562864231221324","volume":"17","author":"L Palaiodimou","year":"2024","unstructured":"Palaiodimou L, Katsanos AH, Turc G, Romoli M, Theodorou A, Lemmens R, et al. Tenecteplase for the treatment of acute ischemic stroke in the extended time window: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2024;17:17562864231221324.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"1228_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103\u201311.","journal-title":"Intern Emerg Med"},{"issue":"2","key":"1228_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40120-024-00684-9","volume":"14","author":"Y Hu","year":"2025","unstructured":"Hu Y, Wu S, Zhang H, Wang K, Zhang L, Ma Y, et al. Efficacy and safety of various intravenous thrombolytics for acute ischemic stroke (AIS) at various dosages: a systematic review and network meta-analysis. Neurol Ther. 2025;14(2):491\u2013523.","journal-title":"Neurol Ther"},{"issue":"3","key":"1228_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108230","volume":"34","author":"S Shahid","year":"2025","unstructured":"Shahid S, Saeed H, Iqbal M, Batool A, Masood MB, Ahmad MH, et al. Comparative efficacy and safety of tissue plasminogen activators (tPA) in acute ischemic stroke: a systematic review and network meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis. 2025;34(3):108230.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"9","key":"1228_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790\u20139.","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"1228_CR14","unstructured":"Agency EM. 1. GLOSSARY. International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice (ICH GCP). 2018. https:\/\/ichgcp.net\/1-glossary. Accessed 26 Mar 2025."},{"issue":"2","key":"1228_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000339675","volume":"34","author":"RC Seet","year":"2012","unstructured":"Seet RC, Rabinstein AA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis. 2012;34(2):106\u201314.","journal-title":"Cerebrovasc Dis"},{"issue":"9558","key":"1228_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","volume":"369","author":"N Wahlgren","year":"2007","unstructured":"Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275\u201382.","journal-title":"Lancet"},{"issue":"2","key":"1228_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"key":"1228_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"4","key":"1228_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082.","journal-title":"PLoS Med"},{"issue":"2","key":"1228_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","volume":"106","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, et al. Netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023;106(2):1\u201340.","journal-title":"J Stat Softw"},{"issue":"1","key":"1228_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/09622802221125913","volume":"32","author":"J Guo","year":"2023","unstructured":"Guo J, Xiao M, Chu H, Lin L. Meta-analysis methods for risk difference: a comparison of different models. Stat Methods Med Res. 2023;32(1):3\u201321.","journal-title":"Stat Methods Med Res"},{"key":"1228_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073141","volume":"381","author":"MH Murad","year":"2023","unstructured":"Murad MH, Wang Z, Zhu Y, Saadi S, Chu H, Lin L. Methods for deriving risk difference (absolute risk reduction) from a meta-analysis. BMJ. 2023;381:e073141.","journal-title":"BMJ"},{"issue":"1","key":"1228_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12874-021-01397-5","volume":"21","author":"KJ Rosenberger","year":"2021","unstructured":"Rosenberger KJ, Duan R, Chen Y, Lin L. Predictive P-score for treatment ranking in Bayesian network meta-analysis. BMC Med Res Methodol. 2021;21(1):213.","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"1228_CR24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7\u20138","key":"1228_CR25","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7\u20138):932\u201344.","journal-title":"Stat Med"},{"issue":"7109","key":"1228_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"1","key":"1228_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12874-020-01075-y","volume":"20","author":"G Rucker","year":"2020","unstructured":"Rucker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Riley RD, Schwarzer G. The statistical importance of a study for a network meta-analysis estimate. BMC Med Res Methodol. 2020;20(1):190.","journal-title":"BMC Med Res Methodol"},{"key":"1228_CR28","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14770.1","volume":"7","author":"T Papakonstantinou","year":"2018","unstructured":"Papakonstantinou T, Nikolakopoulou A, Rucker G, Chaimani A, Schwarzer G, Egger M, et al. Estimating the contribution of studies in network meta-analysis: paths, flows and streams. F1000Res. 2018;7:610.","journal-title":"F1000Res"},{"issue":"8989","key":"1228_CR29","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S0140-6736(95)92049-8","volume":"346","author":"L Candelise","year":"1995","unstructured":"Candelise L. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346(8989):1509\u201314.","journal-title":"Lancet"},{"issue":"13","key":"1228_CR30","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/jama.1995.03530130023023","volume":"274","author":"W Hacke","year":"1995","unstructured":"Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017\u201325.","journal-title":"JAMA"},{"issue":"12","key":"1228_CR31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jama.1996.03540120039031","volume":"276","author":"GA Donnan","year":"1996","unstructured":"Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) trial study group. JAMA. 1996;276(12):961\u20136.","journal-title":"JAMA"},{"issue":"3","key":"1228_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM199607183350301","volume":"335","author":"M Hommel","year":"1996","unstructured":"Multicenter Acute Stroke Trial-Europe Study G, Hommel M, Cornu C, Boutitie F, Boissel JP. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335(3):145\u201350.","journal-title":"N Engl J Med"},{"issue":"9136","key":"1228_CR33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","volume":"352","author":"W Hacke","year":"1998","unstructured":"Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352(9136):1245\u201351.","journal-title":"Lancet"},{"issue":"21","key":"1228_CR34","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.282.21.2019","volume":"282","author":"WM Clark","year":"1999","unstructured":"Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA. 1999;282(21):2019\u201326.","journal-title":"JAMA"},{"issue":"13","key":"1228_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","volume":"359","author":"W Hacke","year":"2008","unstructured":"Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"1228_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(08)70267-9","volume":"8","author":"W Hacke","year":"2009","unstructured":"Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (dias-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8(2):141\u201350.","journal-title":"Lancet Neurol"},{"issue":"9834","key":"1228_CR37","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","volume":"379","author":"P Sandercock","year":"2012","unstructured":"group ISTc, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352\u201363.","journal-title":"Lancet"},{"issue":"6","key":"1228_CR38","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1474-4422(15)00047-2","volume":"14","author":"GW Albers","year":"2015","unstructured":"Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Gronning BA, et al. Safety and efficacy of desmoteplase given 3\u20139 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015;14(6):575\u201384.","journal-title":"Lancet Neurol"},{"issue":"24","key":"1228_CR39","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1515510","volume":"374","author":"CS Anderson","year":"2016","unstructured":"Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374(24):2313\u201323.","journal-title":"N Engl J Med"},{"issue":"12","key":"1228_CR40","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1161\/STROKEAHA.116.013715","volume":"47","author":"R von Kummer","year":"2016","unstructured":"von Kummer R, Mori E, Truelsen T, Jensen JS, Gronning BA, Fiebach JB, et al. Desmoteplase 3 to 9 hours after major artery occlusion stroke: the DIAS-4 trial (efficacy and safety study of desmoteplase to treat acute ischemic stroke). Stroke. 2016;47(12):2880\u20137.","journal-title":"Stroke"},{"issue":"10","key":"1228_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","volume":"16","author":"N Logallo","year":"2017","unstructured":"Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Ronning OM, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781\u20138.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1228_CR42","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1804355","volume":"379","author":"G Thomalla","year":"2018","unstructured":"Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379(7):611\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"1228_CR43","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","volume":"380","author":"H Ma","year":"2019","unstructured":"Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795\u2013803.","journal-title":"N Engl J Med"},{"issue":"5","key":"1228_CR44","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/1747493019840938","volume":"14","author":"P Ringleb","year":"2019","unstructured":"Ringleb P, Bendszus M, Bluhmki E, Donnan G, Eschenfelder C, Fatar M, et al. Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection. Int J Stroke. 2019;14(5):483\u201390.","journal-title":"Int J Stroke"},{"issue":"5","key":"1228_CR45","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1161\/STROKEAHA.119.028127","volume":"51","author":"M Koga","year":"2020","unstructured":"Koga M, Yamamoto H, Inoue M, Asakura K, Aoki J, Hamasaki T, et al. Thrombolysis with alteplase at 0.6 mg\/kg for stroke with unknown time of onset: a randomized controlled trial. Stroke. 2020;51(5):1530\u20138.","journal-title":"Stroke"},{"issue":"9","key":"1228_CR46","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1474-4422(21)00210-6","volume":"20","author":"EI Gusev","year":"2021","unstructured":"Gusev EI, Martynov MY, Nikonov AA, Shamalov NA, Semenov MP, Gerasimets EA, et al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021;20(9):721\u20138.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1228_CR47","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S1474-4422(22)00124-7","volume":"21","author":"CE Kvistad","year":"2022","unstructured":"Kvistad CE, Naess H, Helleberg BH, Idicula T, Hagberg G, Nordby LM, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022;21(6):511\u20139.","journal-title":"Lancet Neurol"},{"issue":"10347","key":"1228_CR48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","volume":"400","author":"BK Menon","year":"2022","unstructured":"Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161\u20139.","journal-title":"Lancet"},{"issue":"2","key":"1228_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(22)00484-7","volume":"22","author":"MB Roaldsen","year":"2023","unstructured":"Roaldsen MB, Eltoft A, Wilsgaard T, Christensen H, Engelter ST, Indredavik B, et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2023;22(2):117\u201326.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1228_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.25415","volume":"6","author":"H Song","year":"2023","unstructured":"Song H, Wang Y, Ma Q, Feng W, Liu R, Lv X, et al. Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial. JAMA Netw Open. 2023;6(7):e2325415.","journal-title":"JAMA Netw Open"},{"issue":"10444","key":"1228_CR51","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/S0140-6736(24)00921-8","volume":"403","author":"SB Coutts","year":"2024","unstructured":"Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, et al. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. Lancet. 2024;403(10444):2597\u2013605.","journal-title":"Lancet"},{"issue":"24","key":"1228_CR52","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","volume":"390","author":"S Li","year":"2024","unstructured":"Li S, Gu HQ, Li H, Wang X, Jin A, Guo S, et al. Reteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2024;390(24):2264\u201373.","journal-title":"N Engl J Med"},{"issue":"3","key":"1228_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2402980","volume":"391","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Campbell BCV, Schwamm LH, Meng X, Jin A, Parsons MW, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy. N Engl J Med. 2024;391(3):203\u201312.","journal-title":"N Engl J Med"},{"issue":"8","key":"1228_CR54","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S1474-4422(24)00206-0","volume":"23","author":"MW Parsons","year":"2024","unstructured":"Parsons MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, Campbell BCV, Russell ML, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol. 2024;23(8):775\u201386.","journal-title":"Lancet Neurol"},{"issue":"17","key":"1228_CR55","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2024.14721","volume":"332","author":"X Meng","year":"2024","unstructured":"Meng X, Li S, Dai H, Lu G, Wang W, Che F, et al. Tenecteplase vs alteplase for patients with acute ischemic stroke: the ORIGINAL randomized clinical trial. JAMA. 2024;332(17):1437\u201345.","journal-title":"JAMA"},{"issue":"11","key":"1228_CR56","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1474-4422(24)00377-6","volume":"23","author":"KW Muir","year":"2024","unstructured":"Muir KW, Ford GA, Ford I, Wardlaw JM, McConnachie A, Greenlaw N, et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol. 2024;23(11):1087\u201396.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1228_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1474-4422(24)00436-8","volume":"24","author":"S Li","year":"2025","unstructured":"Li S, Gu HQ, Feng B, Li H, Wang X, Dong Q, et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial. Lancet Neurol. 2025;24(1):33\u201341.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1228_CR58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12916-024-03820-2","volume":"23","author":"Y Tao","year":"2025","unstructured":"Tao Y, Gao Y, Zhao L, Xu Y, Jiang C, Liu K, et al. Effect of intravenous urokinase vs best medicine treatment on functional outcome for patients with acute minor stroke (TRUST): a randomized controlled trial. BMC Med. 2025;23(1):6.","journal-title":"BMC Med"},{"issue":"3","key":"1228_CR59","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamaneurol.2024.4688","volume":"82","author":"Y Xiong","year":"2025","unstructured":"Xiong Y, Meng X, Jin A, Campbell BCV, Xu A, Dong Q, et al. Prourokinase vs standard care for patients with mild ischemic stroke: the PUMICE randomized clinical trial. JAMA Neurol. 2025;82(3):258\u201366.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1228_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2023-002998","volume":"8","author":"L Liu","year":"2023","unstructured":"Liu L, Li Z, Zhou H, Duan W, Huo X, Xu W, et al. Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update. Stroke Vasc Neurol. 2023;8(6):e3.","journal-title":"Stroke Vasc Neurol."},{"issue":"12","key":"1228_CR61","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"WJ Powers","year":"2019","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2019;50(12):e344\u2013418.","journal-title":"Stroke"},{"issue":"7","key":"1228_CR62","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jamaneurol.2013.406","volume":"70","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Kellert L, Lees KR, Mikulik R, Tatlisumak T, Toni D. Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the safe implementation of treatment in stroke international stroke thrombolysis register (SITS-ISTR): an observational study. JAMA Neurol. 2013;70(7):837\u201344.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1228_CR63","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/STROKEAHA.123.043358","volume":"55","author":"N Kamogawa","year":"2024","unstructured":"Kamogawa N, Miwa K, Toyoda K, Jensen M, Inoue M, Yoshimura S, et al. Thrombolysis for wake-up stroke versus non-wake-up unwitnessed stroke: EOS individual patient data meta-analysis. Stroke. 2024;55(4):895\u2013904.","journal-title":"Stroke"},{"issue":"10446","key":"1228_CR64","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1016\/S0140-6736(24)00642-1","volume":"403","author":"NA Hilkens","year":"2024","unstructured":"Hilkens NA, Casolla B, Leung TW, de Leeuw FE. Stroke. Lancet. 2024;403(10446):2820\u201336.","journal-title":"Lancet"},{"issue":"12","key":"1228_CR65","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa1109842","volume":"366","author":"M Parsons","year":"2012","unstructured":"Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099\u2013107.","journal-title":"N Engl J Med"},{"issue":"13","key":"1228_CR66","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jama.2020.1511","volume":"323","author":"BCV Campbell","year":"2020","unstructured":"Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial. JAMA. 2020;323(13):1257\u201365.","journal-title":"JAMA"},{"issue":"10029","key":"1228_CR67","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","volume":"387","author":"M Goyal","year":"2016","unstructured":"Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723\u201331.","journal-title":"Lancet"},{"issue":"9","key":"1228_CR68","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1161\/01.STR.0000177539.72071.f0","volume":"36","author":"DW Kang","year":"2005","unstructured":"Kang DW, Chalela JA, Dunn W, Warach S, Investigators NI-SSC. MRI screening before standard tissue plasminogen activator therapy is feasible and safe. Stroke. 2005;36(9):1939\u201343.","journal-title":"Stroke"},{"issue":"10","key":"1228_CR69","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1161\/STROKEAHA.107.483255","volume":"38","author":"PD Schellinger","year":"2007","unstructured":"Schellinger PD, Thomalla G, Fiehler J, Kohrmann M, Molina CA, Neumann-Haefelin T, et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke. 2007;38(10):2640\u20135.","journal-title":"Stroke"},{"issue":"2","key":"1228_CR70","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/ana.26413","volume":"92","author":"U Fischer","year":"2022","unstructured":"Fischer U, Branca M, Bonati LH, Carrera E, Vargas MI, Platon A, et al. Magnetic resonance imaging or computed tomography for suspected acute stroke: association of admission image modality with acute recanalization therapies, workflow metrics, and outcomes. Ann Neurol. 2022;92(2):184\u201394.","journal-title":"Ann Neurol"},{"issue":"4","key":"1228_CR71","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S1474-4422(15)70017-7","volume":"14","author":"X Huang","year":"2015","unstructured":"Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14(4):368\u201376.","journal-title":"Lancet Neurol"},{"issue":"9727","key":"1228_CR72","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(10)60491-6","volume":"375","author":"KR Lees","year":"2010","unstructured":"Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695\u2013703.","journal-title":"Lancet"},{"issue":"12","key":"1228_CR73","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1161\/STR.0000000000000152","volume":"48","author":"S Yaghi","year":"2017","unstructured":"Yaghi S, Willey JZ, Cucchiara B, Goldstein JN, Gonzales NR, Khatri P, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2017;48(12):e343\u201361.","journal-title":"Stroke"},{"issue":"11","key":"1228_CR74","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1111\/ene.15482","volume":"29","author":"J He","year":"2022","unstructured":"He J, Fu F, Zhang W, Zhan Z, Cheng Z. Prognostic significance of the clinical and radiological haemorrhagic transformation subtypes in acute ischaemic stroke: a systematic review and meta-analysis. Eur J Neurol. 2022;29(11):3449\u201359.","journal-title":"Eur J Neurol"},{"issue":"9","key":"1228_CR75","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(16)30076-X","volume":"15","author":"WN Whiteley","year":"2016","unstructured":"Whiteley WN, Emberson J, Lees KR, Blackwell L, Albers G, Bluhmki E, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15(9):925\u201333.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1228_CR76","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1055\/s-2007-1002763","volume":"14","author":"V Gurewich","year":"1988","unstructured":"Gurewich V. Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action. Semin Thromb Hemost. 1988;14(1):110\u20135.","journal-title":"Semin Thromb Hemost"},{"issue":"7","key":"1228_CR77","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jama.2024.23480","volume":"333","author":"C Liu","year":"2025","unstructured":"Liu C, Guo C, Li F, Yu N, Huang J, Peng Z, et al. Intra-arterial urokinase after endovascular reperfusion for acute ischemic stroke: the POST-UK randomized clinical trial. JAMA. 2025;333(7):589\u201398.","journal-title":"JAMA"},{"issue":"5","key":"1228_CR78","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/STROKEAHA.122.042335","volume":"54","author":"D Rose","year":"2023","unstructured":"Rose D, Cavalier A, Kam W, Cantrell S, Lusk J, Schrag M, et al. Complications of intravenous tenecteplase versus alteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis. Stroke. 2023;54(5):1192\u2013204.","journal-title":"Stroke"},{"issue":"24","key":"1228_CR79","doi-asserted-by":"publisher","first-page":"14889","DOI":"10.18632\/aging.205315","volume":"15","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wan TF, Chen J, Liu L. Tenecteplase versus alteplase for patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Aging (Albany NY). 2023;15(24):14889\u201399.","journal-title":"Aging (Albany NY)"},{"issue":"9","key":"1228_CR80","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209903","volume":"103","author":"L Palaiodimou","year":"2024","unstructured":"Palaiodimou L, Katsanos AH, Turc G, Asimakopoulos AG, Mavridis D, Schellinger PD, et al. Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials. Neurology. 2024;103(9):e209903.","journal-title":"Neurology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01228-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01228-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01228-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:04:08Z","timestamp":1769681048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01228-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01228-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"X.Y. and H.S. described the study concept and designed the study; X.Y., A.H., and X.W. developed the search strategy and full search stress; X.Y., B.Z., A.H., W.S., and J.G. executed the study selection, data extraction, and quality assessment; X.Y., A.H., and H.S. designed and conducted the statistical analysis; X.Y., K.M., and H.L. drafted the manuscript; W.Y. and H.S. made critical revisions to the manuscript for important intellectual content. All authors participated in administrative, technical, or material support. W.Y. and H.S. were responsible for supervision during the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files. The dataset and analysis code used in this study are available from the corresponding author (Dr. H.Q. Song, songhq@xwhosp.org, or Dr. Y. Wang, wilma0106@163.com) upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}